ALTH ($4.57) Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN(R) in Patients with Advanced Non-Small Cell Lung Cancer
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.